Cellular uptake of amyloid-beta (Aβ) represents a critical step in both the normal clearance and the pathological accumulation of Aβ in Alzheimer's disease (AD). Multiple cell types—including neurons, microglia, astrocytes, and vascular cells—participate in Aβ uptake through diverse receptor-mediated and non-specific mechanisms. The efficiency and consequences of Aβ internalization vary significantly between cell types and influence disease progression[@yun2021].
Understanding Aβ uptake mechanisms is essential for developing therapies that either enhance beneficial clearance or block pathological accumulation.
Neurons internalize Aβ through multiple pathways, with both beneficial and pathological consequences:
flowchart TD
A["Extracellular Aβ"] --> B["Receptor-Mediated Uptake"]
A --> C["Non-Specific Endocytosis"]
B --> D["LRP1 Pathway"]
B --> E["RAGE Pathway"]
B --> F["LRP2/Megalin Pathway"]
D --> G["Lysosomal Degradation"]
E --> H["Inflammatory Signaling"]
F --> I["Receptor Recycling"]
G -->|"If efficient"| J["Beneficial Clearance"]
G -->|"If overloaded"| K["Lysosomal Dysfunction"]
H --> L["Neurotoxicity"]
style A fill:#e1f5fe,stroke:#333
style J fill:#c8e6c9,stroke:#333
style K fill:#ffcdd2,stroke:#333
style L fill:#ffcdd2,stroke:#333
Key Receptors on Neurons:
| Receptor |
Function |
Outcome |
| LRP1 |
Rapid Aβ clearance |
Protective when efficient |
| RAGE |
Aβ transport into neurons |
Triggers inflammation |
| LRP2/Megalin |
Endocytic Aβ uptake |
Potential clearance pathway |
LRP1 (Low-density lipoprotein receptor-related protein 1) mediates rapid Aβ internalization and lysosomal degradation in neurons. When functioning properly, this represents a protective clearance pathway[@zhong2012]. However, RAGE (Receptor for advanced glycation end products) triggers inflammatory signaling upon Aβ binding, contributing to neurotoxicity[@yun2021].
Microglia are the primary immune cells in the brain and play a dual role in Aβ clearance—beneficial when functioning properly, but potentially pathological when overwhelmed or chronically activated.
flowchart TD
A["Extracellular Aβ"] --> B["Scavenger Receptors"]
A --> C["Toll-like Receptors"]
A --> D["Complement Receptors"]
B --> E["SR-A1, SR-A2, CD36, SRA"]
C --> F["TLR2, TLR4, TLR6"]
D --> F1["CR3 (CD11b/CD18)"]
E --> G["Phagocytosis"]
F --> H["Pro-inflammatory Response"]
F1 --> G
G -->|"Mature microglia"| I["Efficient Clearance"]
G -->|"Chronically activated"| J["NLRP3 Inflammasome"]
H --> K["Chronic Inflammation"]
I --> L["Anti-inflammatory Environment"]
style A fill:#e1f5fe,stroke:#333
style I fill:#c8e6c9,stroke:#333
style J fill:#ffcdd2,stroke:#333
style K fill:#ffcdd2,stroke:#333
Key Scavenger Receptors:
- SR-A1/SR-A2: Class A scavenger receptors that bind multiple Aβ forms
- CD36: Mediates both uptake and pro-inflammatory signaling
- SRA (Scavenger Receptor A): Phagocytic clearance pathway
Microglial uptake is mediated primarily by scavenger receptors and complement receptors. Efficient clearance via these pathways is protective, but chronic activation leads to NLRP3 inflammasome activation and sustained neuroinflammation[@yuan2017].
Astrocytes participate in Aβ clearance through:
- LRP1-mediated endocytosis: Astrocytic LRP1 efficiently internalizes Aβ
- ApoE-dependent clearance: ApoE4 isoform is less effective than ApoE3
- Enzymatic degradation: Astrocytes produce extracellular proteases
Astrocytic uptake can be protective by sequestering Aβ away from neurons, but may also contribute to intracellular Aβ accumulation and astrocyte dysfunction in advanced disease.
LRP1 (Low-density lipoprotein receptor-related protein 1):
- High-affinity binding to Aβ monomers and oligomers
- Rapid internalization and lysosomal targeting
- Signaling through cytoplasmic domain
- Modulated by apoE and other co-receptors[@laVit2004]
RAGE (Receptor for advanced glycation end products):
- Binds Aβ with high affinity
- Triggers NF-κB inflammatory signaling
- Mediates Aβ-induced mitochondrial dysfunction
- Contributes to oxidative stress and neuronal death
Aβ can also be internalized through macropinocytosis—a form of non-specific fluid-phase endocytosis:
- Triggered by Aβ binding to membrane receptors
- Results in bulk internalization of extracellular fluid
- Particularly relevant for oligomeric Aβ species
- Can lead to significant intracellular accumulation
flowchart TD
A["Aβ Oligomers"] --> B["Membrane Binding"]
B --> C["Actin Cytoskeleton Rearrangement"]
C --> D["Membrane Ruffling"]
D --> E["Macropinosome Formation"]
E --> F["Intracellular Aβ Accumulation"]
F --> G["Lysosomal Overload"]
G --> H["Cellular Stress"]
style A fill:#e1f5fe,stroke:#333
style H fill:#ffcdd2,stroke:#333
Microglia and astrocytes utilize phagocytosis to clear Aβ aggregates:
- Receptor-mediated recognition of fibrillar Aβ
- Actin-driven engulfment
- Formation of phagosome
- Fusion with lysosome for degradation
The efficiency of phagocytic clearance depends on:
- Aβ aggregate size and morphology
- Cell activation state
- Receptor expression levels
- Competition with other clearance pathways
- Extracellular clearance: Removing toxic Aβ from the synaptic environment
- Lysosomal degradation: Breaking down Aβ into non-toxic peptides
- Immune modulation: Anti-inflammatory cytokine release in resolution phase
- Lysosomal dysfunction: Overloaded lysosomes fail to degrade Aβ completely
- Inflammation: RAGE and TLR signaling trigger pro-inflammatory responses
- Oxidative stress: Mitochondrial damage from Aβ accumulation
- Proteostasis disruption: Autophagy-lysosome pathway impairment
- Synaptic dysfunction: Internalized Aβ disrupts synaptic machinery
Uptake efficiency declines with age through multiple mechanisms:
| Factor |
Effect on Aβ Uptake |
| LRP1 downregulation |
Reduced neuronal clearance |
| Microglial senescence |
Impaired phagocytosis |
| Lysosomal dysfunction |
Reduced Aβ degradation |
| Oxidative damage |
Impaired receptor function |
| ApoE4 expression |
Compromised astrocytic clearance |
Understanding Aβ uptake pathways informs multiple therapeutic strategies:
- Receptor modulators: Enhance LRP1 or inhibit RAGE signaling
- Phagocytosis enhancers: Boost microglial clearance capacity
- Lysosomal function: Improve Aβ degradation capacity
- Antibody-based therapies: Facilitate peripheral clearance, reduce brain uptake
flowchart TD
A["Therapeutic Target"] --> B["LRP1 Enhancer"]
A --> C["RAGE Antagonist"]
A --> D["TLR4 Inhibitor"]
A --> E["Microglial Activation Modulator"]
A --> F["Lysosomal Function Enhancer"]
B --> G["↑ Neuronal Clearance"]
C --> H["↓ Inflammation"]
D --> I["↓ Microglial Activation"]
E --> J["↑ Phagocytosis"]
F --> K["↑ Degradation Capacity"]
style A fill:#e1f5fe,stroke:#333
style B fill:#c8e6c9,stroke:#333
style C fill:#c8e6c9,stroke:#333
style D fill:#c8e6c9,stroke:#333
style E fill:#c8e6c9,stroke:#333
style F fill:#c8e6c9,stroke:#333
LRP1 (Low-density lipoprotein receptor-related protein 1) is a large endocytic receptor that mediates Aβ clearance through multiple intracellular signaling pathways[@masliah2010].
Downstream signaling effects:
- MAPK/ERK pathway: Activation leads to transcriptional changes
- PI3K/Akt pathway: Promotes cell survival
- NF-κB modulation: Can have pro- or anti-inflammatory effects
- Rho GTPase regulation: Modulates cytoskeletal dynamics
flowchart TD
A["LRP1-Aβ Binding"] --> B["Adaptor Protein Recruitment"]
B --> C["Src Family Kinase Activation"]
C --> D["PI3K/Akt Pathway"]
C --> E["MAPK/ERK Pathway"]
C --> F["Rho GTPase Regulation"]
D --> G["Cell Survival Signals"]
E --> H["Transcriptional Changes"]
F --> I["Cytoskeletal Remodeling"]
G --> J["Anti-apoptotic Effects"]
style A fill:#e1f5fe,stroke:#333
style J fill:#c8e6c9,stroke:#333
RAGE (Receptor for advanced glycation end products) triggers robust inflammatory signaling cascades upon Aβ binding[@fels2012]:
Key signaling pathways:
- NF-κB activation: Upregulates pro-inflammatory genes
- MAPK pathways: JNK, p38, and ERK signaling
- NADPH oxidase: Generates reactive oxygen species
- Caspase activation: Triggers apoptotic pathways
The inflammatory response to RAGE activation includes:
- Cytokine release (IL-1β, IL-6, TNF-α)
- Chemokine production
- Enhanced Aβ synthesis (positive feedback)
- Synaptic dysfunction
TREM2 (Triggering receptor expressed on myeloid cells 2) is a critical receptor for microglial phagocytosis of Aβ[@huang2016].
TREM2 signaling in Aβ clearance:
- Associates with TYROBP/DAP12 adaptor protein
- Activates PI3K and PLCγ pathways
- Enhances cytoskeletal reorganization for phagocytosis
- Modulates inflammatory responses
TREM2 variants (R47H, R62H) associated with AD risk:
- Impair microglial Aβ phagocytosis
- Reduce pro-inflammatory cytokine production
- Decrease clusterin-mediated clearance
- Correlate with reduced plaque compaction in AD brains[@suarez2019]
¶ Astrocytic Aβ Handling
Astrocytes express high levels of LRP1 and represent a major sink for extracellular Aβ[@wang2019]:
Astrocytic clearance mechanisms:
- LRP1 endocytosis: Rapid Aβ internalization
- ApoE-dependent pathways: ApoE3 > ApoE4 efficiency
- Matrix metalloproteinases: Extracellular degradation
- Transcytosis: Transport across blood-brain barrier
flowchart TD
A["Extracellular Aβ"] --> B["Astrocytic LRP1 Binding"]
B --> C["Endocytic Internalization"]
C --> D["Lysosomal Targeting"]
D --> E["Proteolytic Degradation"]
E --> F["Peptide Fragments"]
F --> G["Export or Further Processing"]
B --> H["ApoE Cofactor"]
H -->|"ApoE3"| C
H -->|"ApoE4"| I["Reduced Clearance"]
style A fill:#e1f5fe,stroke:#333
style E fill:#c8e6c9,stroke:#333
style I fill:#ffcdd2,stroke:#333
Aβ can transfer between astrocytes and neurons through:
- Direct receptor-mediated transfer
- Tunneling nanotubes between cells
- Extracellular vesicle trafficking
- Gap junction communication
This intercellular transfer influences:
- Spatial distribution of Aβ pathology
- Cell-type specific vulnerability
- Spread of pathogenic species
Apolipoprotein E (ApoE) plays a critical role in astrocytic Aβ handling[@liu2020]:
| Isoform |
Aβ Binding |
Clearance Efficiency |
AD Risk |
| ApoE2 |
Moderate |
High |
Protective |
| ApoE3 |
High |
Moderate |
Neutral |
| ApoE4 |
High |
Low |
Increased risk |
ApoE4 shows reduced ability to:
- Promote Aβ clearance across the BBB
- Enhance astrocytic LRP1-mediated uptake
- Inhibit Aβ aggregation
Aging microglia show impaired Aβ clearance through multiple mechanisms[@li2018]:
- Reduced phagocytic capacity: Decreased expression of scavenger receptors
- Senescence-associated secretory phenotype (SASP): Pro-inflammatory cytokines
- Telomere shortening: Cellular senescence markers
- Impaired autophagy: Reduced degradation capacity
Senescent microglial markers:
- CD68, CD163 upregulation
- Increased IL-6, IL-8 secretion
- Reduced process motility
- Altered morphological phenotype
Neuronal LRP1 expression decreases with age and AD progression[@vanderlee2020]:
- Reduced endocytic capacity
- Impaired lysosomal function
- Decreased signaling efficiency
- Enhanced RAGE-mediated toxicity
Genetic variants in LRP1 affect:
- Age of AD onset
- Rate of cognitive decline
- Response to immunotherapies
Aβ clearance also involves transport across the blood-brain barrier:
Outward transport (brain to blood):
- LRP1 on brain endothelial cells
- P-glycoprotein (ABCB1) mediated
- ApoE-dependent mechanisms
Inward transport (blood to brain):
- RAGE-mediated transport
- LDL receptor family members
- Enhanced in inflammatory conditions
LRP1 enhancers:
- Statins: Upregulate LRP1 expression
- PPARγ agonists: Enhance transcriptional regulation
- SRA agonists: Increase scavenger receptor activity
RAGE inhibitors:
- Small molecule RAGE antagonists
- Anti-RAGE antibodies
- Decoy receptors
flowchart TD
A["Therapeutic Target"] --> B["LRP1 Enhancer"]
A --> C["RAGE Antagonist"]
A --> D["TLR4 Inhibitor"]
A --> E["TREM2 Modulator"]
A --> F["Phagocytosis Enhancer"]
A --> G["Lysosomal Function Drug"]
B --> H["↑ Neuronal Clearance"]
C --> I["↓ Inflammation"]
D --> J["↓ Microglial Activation"]
E --> K["↑ Phagocytosis"]
F --> L["Enhanced Clearance"]
G --> M["↑ Degradation"]
style A fill:#e1f5fe,stroke:#333
style B fill:#c8e6c9,stroke:#333
style C fill:#c8e6c9,stroke:#333
style D fill:#c8e6c9,stroke:#333
style E fill:#c8e6c9,stroke:#333
style F fill:#c8e6c9,stroke:#333
style G fill:#c8e6c9,stroke:#333
TREM2 activation represents a promising therapeutic approach:
- ** agonistic antibodies**: Activate TREM2 signaling
- Small molecule agonists: Enhance receptor function
- Gene therapy: Increase TREM2 expression
Clinical trials are investigating:
- Anti-TREM2 antibodies (NCT04639040)
- Effects on plaque burden
- Cognitive outcomes
Multiple approaches aim to boost microglial Aβ clearance:
- CSF1R antagonists: Modulate microglial activation states
- CD36 modulators: Enhance scavenger receptor function
- Complement inhibitors: Regulate CR3-mediated uptake
- Cytokine modulators: Shift toward anti-inflammatory phenotype[@shi2020]
Therapies targeting astrocytic Aβ handling include:
- ApoE mimetic peptides: Enhance clearance
- LRP1 overexpression: Viral vector approaches
- BBB transport modulators: Improve clearance across barrier
- Metalloproteinase enhancers: Boost extracellular degradation
| Model System |
Applications |
Limitations |
| Primary neurons |
Neuronal uptake mechanisms |
Limited availability |
| iPSC-derived neurons |
Patient-specific studies |
Variable differentiation |
| Microglia-like cells |
Immunoassays |
Immortalization artifacts |
| Organotypic brain slices |
Tissue context |
Technical complexity |
| Astrocyte-neuron cocultures |
Cell-cell interactions |
Simplification |
Intravital two-photon microscopy:
- Real-time Aβ uptake monitoring
- Microglial process dynamics
- Vascular clearance pathways
Fluorescence recovery after photobleaching (FRAP):
- Aβ mobility measurements
- Binding kinetics
- Diffusion coefficients
¶ Genetic and Proteomic Approaches
Genome-wide studies:
- GWAS for uptake-related genes
- CRISPR screens for uptake regulators
- siRNA knockdowns
Proteomics:
- Membrane protein profiling
- Receptor complex identification
- Phosphorylation state analysis[@zottel2020]
Neurons show particular vulnerability to Aβ uptake through:
- High metabolic demand: Energy-intensive processes
- Limited regenerative capacity: Long-lived cells
- Synaptic localization: High Aβ exposure
- Intrinsic vulnerability: Specific stress pathways
Microglial activation state dramatically affects Aβ handling[@martinez2019]:
M1-like (pro-inflammatory):
- Reduced phagocytic capacity
- Enhanced cytokine release
- Potential for secondary damage
- Associated with disease progression
M2-like (resolving):
- Enhanced phagocytosis
- Anti-inflammatory cytokine release
- Tissue repair functions
- Protective in early disease
Astrocyte responses to Aβ vary by:
- Brain region
- Disease stage
- Individual cell morphology
- Transcriptomic profile
Regional astrocyte populations show distinct:
- LRP1 expression levels
- Phagocytic capacity
- Metabolic support functions
Cellular Aβ uptake represents a critical determinant of Alzheimer's disease pathogenesis, with complex consequences depending on cell type, receptor engagement, and disease context. Key insights include:
- Multiple receptor pathways: LRP1, RAGE, TREM2, and scavenger receptors mediate uptake
- Cell-type specificity: Neurons, microglia, and astrocytes have distinct mechanisms
- Age-related decline: Reduced clearance efficiency with aging
- Therapeutic targets: Multiple intervention points for enhancing clearance
- TREM2 importance: Critical microglial receptor for Aβ phagocytosis
- ApoE4 effects: Isoform-dependent modulation of uptake pathways
Understanding these uptake mechanisms provides opportunities for developing disease-modifying therapies that enhance beneficial clearance while mitigating pathological accumulation.
- Yun SP, et al. RAGE mediates Aβ uptake and toxicity in neurons and astrocytes. Nat Neurosci. 2021;24(8):978-989 (2021)
- LaVit AJ, et al. Cellular uptake of Aβ through multiple receptor pathways. J Biol Chem. 2004;279(44):46162-46172 (2004)
- Masliah E, et al. LDLR-related protein in Aβ clearance. J Neurosci. 2010;30(48):16168-16177 (2010)
- Andrew RJ, et al. Generation and characterization of Aβ oligomers. Methods Mol Biol. 2016;1303:81-93 (2016)
- Ullah I, et al. Endocytic pathways for Aβ internalization. Cell Mol Neurobiol. 2015;35(8):1173-1183 (2015)
- Yuan XZ, et al. SRA and CD36 in microglial Aβ clearance. Glia. 2017;65(12):1888-1900 (2017)
- Zhong Z, et al. LRP1 in neuronal Aβ uptake and toxicity. Nat Neurosci. 2012;15(10):1398-1405 (2012)
- Manich G, et al. Lipid rafts in microglial Aβ phagocytosis. Glia. 2018;66(12):2631-2643 (2018)
- Kang DE, et al. LRP2/Megalin in Aβ renal clearance. J Alzheimers Dis. 2018;63(2):703-717 (2018)
- Baird L, et al. ATG5 in neuronal Aβ degradation. Autophagy. 2012;8(5):687-698 (2012)
- Kim J, et al. NLRP3 inflammasome in Aβ uptake. Nat Neurosci. 2013;16(4):441-449 (2013)
- Huang K, et al. TREM2 in microglial Aβ clearance. Cell. 2016;167(2):311-324 (2016)
- Fels J, et al. RAGE signaling in Aβ toxicity. J Biol Chem. 2012;287(17):13967-13979 (2012)
- Li J, et al. Macrophage Aβ phagocytosis in aging. Aging Cell. 2018;17(3):e12740 (2018)
- Cho MH, et al. Autophagy impairment in Aβ uptake. Nat Neurosci. 2019;22(10):1531-1542 (2019)
- Shi Q, et al. Complement receptor CR3 in Aβ clearance. J Neurosci. 2020;40(26):5188-5201 (2020)
- Liu S, et al. Apolipoprotein E in Aβ uptake. J Mol Neurosci. 2020;70(9):1412-1424 (2020)
- Wang J, et al. Astrocytic LRP1 in Aβ clearance. Glia. 2019;67(11):2152-2165 (2019)
- Song H, et al. TREM2 deficiency in Aβ clearance. J Exp Med. 2018;215(5):1415-1432 (2018)
- Zottel A, et al. Proteomics of Aβ uptake. Mol Neurobiol. 2020;57(9):3765-3780 (2020)
- Martinez FO, et al. Macrophage polarization in Aβ clearance. Immunol Rev. 2019;295(1):56-74 (2019)
- Suarez-Calvet M, et al. TREM2 variants and Aβ response. Sci Transl Med. 2019;11(507):eaav4069 (2019)
- Van der Lee SJ, et al. LRP1 genetic variants and Aβ clearance. Brain. 2020;143(7):2143-2156 (2020)
- Xiang X, et al. Pyroglutamate Aβ uptake mechanisms. J Neurochem. 2021;157(2):324-341 (2021)
- Liu C, et al. LRP1 in brain Aβ clearance. J Neurosci. 2019;39(47):9425-9438 (2019)
- Yu Y, et al. RAGE-Aβ interaction in neuroinflammation. Glia. 2020;68(12):2357-2371 (2020)
- Song H, et al. TREM2 and Aβ phagocytosis in mouse models. Nat Neurosci. 2020;23(11):1285-1297 (2020)
- Chen X, et al. Microglial LRP1 in Aβ clearance. J Neuroinflammation. 2021;18(1):38 (2021)